Evidence map›Paper›PMID 40976786›Full record

ArticleThe EMBO journal2025

Telomeric DNA damage response mediates neurotoxicity of Aβ42 oligomers in Alzheimer's disease.

Sara Sepe, Federica Rey, Alexandra Mancheno-Ferris, Alessandra Bigi, Giulia Fani, Devid Damiani, Matteo Cabrini, Eugenia Marinelli, Julio Aguado, Liliana Contu and 7 more

Abstract read
In one paragraph

Article in The EMBO journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sara SepeIFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID http://orcid.org/0000-0002-9884-9189
Federica ReyIFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID http://orcid.org/0000-0001-7944-3143
Alexandra Mancheno-FerrisIFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID http://orcid.org/0000-0002-2689-8483
Alessandra BigiDepartment of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence, Italy.ORCID http://orcid.org/0000-0002-1067-6288
Giulia FaniDepartment of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence, Italy.
Devid DamianiCenter for Human Technologies, Non-coding RNAs and RNA-based Therapeutics, Istituto Italiano di Tecnologia (IIT), Genova, Italy.
Matteo CabriniIFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
Eugenia MarinelliIFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
Julio AguadoIFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
Liliana ContuCenter for Human Technologies, Non-coding RNAs and RNA-based Therapeutics, Istituto Italiano di Tecnologia (IIT), Genova, Italy.
Alessia di LilloIFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
Sara BoggioIFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
Sara TavellaIFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
Ilaria RossoIFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.
Stefano GustincichCenter for Human Technologies, Non-coding RNAs and RNA-based Therapeutics, Istituto Italiano di Tecnologia (IIT), Genova, Italy.
Fabrizio ChitiDepartment of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence, Italy.ORCID http://orcid.org/0000-0002-1330-1289
Fabrizio d'Adda di FagagnaIFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy. fabrizio.dadda@igm.cnr.it.ORCID http://orcid.org/0000-0002-9603-5966

Funding

EC | European Research Council (ERC) ERC advanced grant -TELORNAGING-835103EC | European Research Council (ERC) ERC POC TELOVACCINE - 101113229European Commission (EC) Investment CN3 National Center for Gene Therapy and Drugs based on RNA TechnologyEuropean Commission (EC) NEXTGENERATIONEUEuropean Commission (EC) Next generation EU,PE8 Project Age-ItFondazione AIRC per la ricerca sul cancro ETS (AIRC) AIRC 5×1000 21091Fondazione AIRC per la ricerca sul cancro ETS (AIRC) AIRC-IG 21762Fondazione AIRC per la ricerca sul cancro ETS (AIRC) AIRC-IG 30471Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica (AriSLA) FG_24/2020Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica (AriSLA) FG_24_2020Fondazione Regionale per la Ricerca Biomedica (Regione Lombardia) EJPRD19-206 PROGERIA,GA 825575Fondazione Telethon (FT) GMR23T2007Ministero dell'Università e della Ricerca (MUR) (PRIN) 2020CXFL4TMinistero dell'Università e della Ricerca (MUR) (PRIN) 2022R7LH5TPOR FESR InterSLA DSB.AD004.294
6 · The paper itself

Abstract

Ageing is the major risk factor for Alzheimer's disease (AD), the most common neurodegenerative disorder. DNA damage is a hallmark of ageing, particularly when occurring at telomeres, genomic regions vulnerable to oxidative damage and often challenging for the cell to repair. Here, we show that brains of 3xTg-AD mice, an established AD model characterized by amyloid-β (Aβ)-induced pathology, exhibit increased activation of DNA damage response (DDR) pathways at telomeres. Exposure of mouse primary hippocampal neurons to 42-residue Aβ (Aβ42) oligomers, a significant pathogenetic contributor to AD, triggers telomeric DDR by increasing the levels of reactive oxygen species caused by calcium imbalance. Antisense oligonucleotides targeting non-coding RNAs generated at damaged telomeres in vivo (in 3xTg-AD mice) and in vitro reduce neurotoxicity in iPSC-derived human cortical neurons and mouse primary neurons while inhibiting Aβ42-induced telomeric DDR, and restore transcriptional pathways altered by Aβ and found dysregulated in AD patients. These results unveil an unexpected role of telomeric DNA damage responses in Alzheimer's disease pathogenesis, and suggest a novel target for the development of RNA-based therapies.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesDNA DamageNeuronsPeptide FragmentsTelomereAnimalsCells, CulturedDisease Models, AnimalHippocampusHumansMiceMice, TransgenicReactive Oxygen SpeciesAmyloid beta-Peptidesamyloid beta-protein (1-42)Peptide FragmentsReactive Oxygen SpeciesAgingAlzheimer’s disease (AD)ASODNA damage response (DDR)Telomeres

Identifiers

PMID40976786
PMCPMC12583505

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.